Technology evaluation: alicaforsen (Isis).

CURRENT OPINION IN MOLECULAR THERAPEUTICS（2005）

引用 25|浏览4

暂无评分

摘要

Isis is developing alicaforsen, an RNase H-dependent antisense inhibitor of intercellular adhesion molecule-1, for the potential treatment of ulcerative colitis. The therapy is currently undergoing phase II clinical trials.

查看译文

关键词

technology evaluation,alicaforsen,isis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要